/assets/images/provider/photos/2823060.jpg)
GLP-1 receptor agonists mimic a naturally occurring hormone—glucagon-like peptide-1—that helps regulate blood sugar, slow digestion, and promote a feeling of fullness.
They can:
Improve post-meal and fasting glucose
Help with weight reduction
Lower cardiovascular risk in specific patient populations
Reduce appetite and slow gastric emptying
Forms: Weekly injection (Ozempic, Wegovy); daily oral tablet (Rybelsus)
Strongest weight-loss results among current GLP-1s (especially Wegovy)
Excellent A1c reduction
Cardiovascular benefit demonstrated in high-risk patients
Weekly injection is convenient
Oral option available for patients hesitant about injections
Higher rates of GI side effects (nausea, vomiting) compared to some others
More costly than older GLP-1 medications
Oral version must be taken on an empty stomach with strict timing
Insurance coverage can be challenging, especially for weight-loss versions
Form: Weekly injection
Note: Technically a dual GIP/GLP-1 agonist, offering potentially greater metabolic effects
Currently offers the most significant weight-loss outcomes in clinical studies
Excellent A1c reduction—often superior to semaglutide
Weekly dosing is convenient
Good option for patients with severe insulin resistance
GI effects can be similar or slightly more intense during dose escalation
Insurance barriers can be substantial for weight-loss indications
Long-term cardiovascular outcome data are still emerging
Higher cost compared to older GLP-1 agents
Form: Weekly injection
Easy-to-use auto-injector—very patient-friendly
Good glucose-lowering effect
Cardiovascular benefit in patients with type 2 diabetes
Well-tolerated with a predictable side-effect profile
Less potent for weight loss compared to semaglutide and tirzepatide
Some patients experience injection-site discomfort due to larger needle gauge
Limited dose escalation compared to newer medications
Forms: Daily injection (Victoza for diabetes; Saxenda for weight loss)
Strong cardiovascular protection (Victoza)
Effective for weight loss (Saxenda), though less dramatic than weekly alternatives
Daily dosing allows finer control of tolerance during titration
Daily injections can impact long-term adherence
Higher likelihood of nausea in the early phase
Less cost-effective compared to weekly GLP-1s
Insurance coverage varies widely
The “best” medication depends on the patient's individual goals, health conditions, and insurance coverage. Physicians typically consider:
Primary goal: weight loss, glucose control, or cardiovascular protection
Existing medical conditions: kidney function, pancreatitis history, gastroparesis
Dosing preference: daily vs. weekly vs. oral
Insurance/affordability: significant factor in real-world care
Tolerance to GI side effects
Need for aggressive A1c reduction
Semaglutide and tirzepatide generally provide the most robust weight and glucose benefits, but older GLP-1 agents can be excellent options depending on patient profiles.
GLP-1 medications represent some of the most impactful advancements in metabolic health. Understanding the differences between each option empowers you to make informed decisions alongside your medical provider. Whether the focus is weight management, diabetes control, or reducing cardiovascular risk, there is likely a GLP-1 therapy suited for you.